EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis

Chang Shu iD, Tao Zhang iD, Jia-Wei Liu iD, Chen-Yu Zhu iD, Rou-Yu Fang iD, Qiu-Ning Sun iD, Nian Li iD, Feng Li iD

Journal of Cosmetic Dermatology · 2026-03 · 25 (3)

DOI: 10.1111/jocd.70799 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 19.03.2026. Verfasst von Chang Shu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, Peo…. Hauptthemen laut MEDLINE: Granuloma, Mesotherapy, Piperidines, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Key Clinical Specialty Construction Project, National Key Clinical Specialty Project of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mesotherapy, a widely utilized minimally invasive cosmetic procedure, carries potential risks of adverse reactions due to non‐standardized protocols and overuse. Delayed granulomatous reactions represent a chronic complication, imposing significant physical and psychological burdens on patients.

Objective

This case series aims to evaluate the efficacy and safety of tofacitinib in managing non‐infectious granulomatous reactions following mesotherapy.

Methods

This retrospective analysis included six patients diagnosed with non‐infectious granulomatous reactions post‐mesotherapy, treated at Peking Union Medical College Hospital between October 2021 and April 2025. All patients received oral tofacitinib. Clinical outcomes, treatment regimens, and safety profiles were assessed.

Results

All six patients demonstrated significant improvement in skin lesion severity, with no treatment‐related adverse events observed during follow‐up.

Conclusion

Oral tofacitinib exhibits promising clinical efficacy and a favorable safety profile for non‐infectious granulomatous reactions induced by mesotherapy, positioning it as a viable therapeutic option during the inflammatory phase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GranulomaMesotherapyPiperidinesProtein Kinase InhibitorsPyrimidinesAdultFemaleHumansAdministration, OralRetrospective StudiesTreatment Outcome

Substanzen

PiperidinesProtein Kinase InhibitorsPyrimidinestofacitinib

Autor:innen und Institutionen

  • Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, People's Republic of China.

ORCID-Profile: Chang Shu, Tao Zhang, Jia-Wei Liu, Chen-Yu Zhu, Rou-Yu Fang, Qiu-Ning Sun, Nian Li, Feng Li

Förderung

  • Beijing Key Clinical Specialty Construction Project
  • National Key Clinical Specialty Project of China

Zitieren

APA

Shu, C., Zhang, T., Liu, J. W., Zhu, C. Y., Fang, R. Y., Sun, Q. N., Li, N., & Li, F. (2026). Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis. Journal of Cosmetic Dermatology, 25(3). https://doi.org/10.1111/jocd.70799

Vancouver

Shu C, Zhang T, Liu JW, Zhu CY, Fang RY, Sun QN, et al. Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis. Journal of Cosmetic Dermatology. 2026;25(3). doi:10.1111/jocd.70799

BibTeX
@article{Shu2026,
  author = {Shu, Chang and Zhang, Tao and Liu, Jia-Wei and Zhu, Chen-Yu and Fang, Rou-Yu and Sun, Qiu-Ning and Li, Nian and Li, Feng},
  title = {Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis},
  journal = {Journal of Cosmetic Dermatology},
  year = {2026},
  volume = {25},
  number = {3},
  doi = {10.1111/jocd.70799}
}
Kostenlos starten →